In the last several years, there have been significant advances in the area of targeted therapies for constitutional genetic disorders. This session will review the targeted molecular therapies for cystic fibrosis, their mechanisms of action, and their impact on patient care.
Molecular Therapies for Cystic Fibrosis
Garry Cutting, MD, Johns Hopkins University, Baltimore, MD, USA
Objectives:
- Describe novel targeted therapies for various genetic disorders.
- Describe the mechanisms of targeted therapies and patient prognosis.
Recording Date: November 16, 2020
Continuing Education Credit Information
CME/CMLE credit: 1.00 hr
Last day to purchase course and CE claim credit: February 16, 2024
Note: Members of AMP can access this at a discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
